# Intravesical oxybutynin for bladder capacity in children with spina bifida: the ‘Place de l’OXybutynine Intravésicale chez le Patient Enfant Neurologique’ (POXIPEN) trial protocol

## TL;DR

This study will test if intravesical oxybutynin improves bladder capacity in children with spina bifida, potentially reducing the need for invasive procedures.

## Contribution

The first prospective, placebo-controlled trial evaluating intravesical oxybutynin in children with neurogenic bladder.

## Key findings

- The trial will assess changes in maximal bladder capacity after intravesical oxybutynin treatment.
- It will evaluate the impact on voiding, urodynamic parameters, and quality of life in children with spina bifida.
- If effective, intravesical oxybutynin could delay invasive treatments and reduce anesthesia risks.

## Abstract

Neurogenic bladder is defined as a dysfunction of the bladder resulting from damage to the central or peripheral nervous systems. Its treatment is based on a progressive therapeutic escalation, rapidly involving invasive therapeutic procedures such as repeated intradetrusor injections and surgery. Given the risk of repeated general anaesthesia in children, there is a need for non‐invasive treatment for young patients who do not respond to or have adverse effects from oral anticholinergic treatment. The ‘Place de l’OXybutynine Intravésicale chez le Patient Enfant Neurologique’ (POXIPEN) trial aims to assess the efficacy of intra‐vesical oxybutynin on bladder capacity in a sample of French children with neurogenic bladder.

The POXIPEN is a multicentre, randomised, double‐blind, placebo‐controlled trial.

The primary outcome is change in maximal bladder capacity after treatment. Secondary outcomes include changes in voiding, urodynamic and ultrasound parameters. We will also assess changes on quality of life and usability of the product.

We aim to randomly assign 60 children with neurogenic bladder secondary to spina bifida and deemed non‐responders to first‐line treatment with oral anticholinergics, to receive intravesical oxybutynin (IVO) or placebo for 4 weeks. Recruitment will start in September 2025. It will be the first prospective study to evaluate the efficacy of IVO in children, with a high level of evidence provided by its design. If IVO proves effective, it could lengthen the delay in therapeutic escalation to invasive procedures, thereby reducing the risk of complications associated with general anaesthesia in children with neurogenic bladder.

This trial is registered with the European Union (EU) Clinical Trials Information System (CTIS) under EU CT Number: 2022–501 902–36‐00 (approved 09.01.2025) and ClinicalTrials.gov under identifier NCT07027020 (registered 18.06.2025).